



## **Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results**

March 24, 2021

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: **DCTH**), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

### **Conference Call Information**

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: March 31, 2021  
Time: 8:00 AM Eastern Time  
Toll Free: 877-407-8035  
International: 201-689-8035

The call will also be available over the Internet and accessible at: <https://www.webcaster4.com/Webcast/Page/2475/40544>

### **About Delcath Systems, Inc.**

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

### **Contact:**

*Delcath Investor Relations*

Email: [investorrelations@delcath.com](mailto:investorrelations@delcath.com)

*Hayden IR*

James Carbonara  
(646)-755-7412  
[james@haydenir.com](mailto:james@haydenir.com)

Delcath Systems, Inc.